Study details
Enrolling now
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Stephanie B. Seminara, MD
NCT IDNCT07224490ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
40
Study length
about 4.3 years
Ages
18–60
Locations
1 site in MA
About this study
This trial is testing a treatment called kisspeptin in people with or without post-COVID-19 syndrome. The goal is to see how the body responds to this treatment by measuring hormone levels before and after giving it.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Kisspeptin 112-121
PhasePhase 1
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Infectious